IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 2133 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (157 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References

 Article Access Statistics
    Viewed1366    
    Printed30    
    Emailed0    
    PDF Downloaded161    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2014  |  Volume : 46  |  Issue : 4  |  Page : 460
 

Comment: Comparison of efficacy, safety and cost-effectiveness of various statins in dyslipidemic diabetic patients


Department of Pharmacology, Kasturba Medical College, Mangalore, Karnataka, India

Date of Web Publication4-Jul-2014

Correspondence Address:
Sanjay Hadigal
Department of Pharmacology, Kasturba Medical College, Mangalore, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.135970

Rights and Permissions



How to cite this article:
Hadigal S, Shenoy K A. Comment: Comparison of efficacy, safety and cost-effectiveness of various statins in dyslipidemic diabetic patients. Indian J Pharmacol 2014;46:460

How to cite this URL:
Hadigal S, Shenoy K A. Comment: Comparison of efficacy, safety and cost-effectiveness of various statins in dyslipidemic diabetic patients. Indian J Pharmacol [serial online] 2014 [cited 2021 Feb 26];46:460. Available from: https://www.ijp-online.com/text.asp?2014/46/4/460/135970


Sir,

I read with interest the above mentioned article. [1] However, I had a few comments to make regarding the same. The method used to arrive at the particular sample size was not mentioned and neither was the power of the study. Some of the data mentioned in the written content did not correlate with the data that was mentioned in the graph. The authors mentioned that atorvastatin reduced LDL-C the most at a dose of 40 mg (15.9%). However, [Table 3] clearly mentions that atorvastatin at a dose of 20 mg reduced LDL-C the most (21.2%). In [Figure 1]b, the footnote of the graph wrongly mentions microalbuminia instead of microalbuminuria.

As the authors had used the term cost-effectiveness in the study title, it would have been better if they had shed more light on the pharmacoeconomic analysis. They have solely mentioned the acquisition cost of rosuvastatin when compared to atorvastatin. A cost-effective analysis with the calculation of the Incremental Cost Effectiveness Ratio would have been more appropriate and insightful.[2]



 
  References Top

1.Bener A, Dogan M, barakat L, Al-Hamaq AO. Comparison of efficacy, safety, and cost-effectiveness of various statins in dyslipidemic diabetic patients. Indian J Pharmacol 2014;46:88-93.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.Lisa AS. Pharmacoeconomics: Principles, Methods and Applications In: Joseph TD, Robert LT, Gary CY, Barbara GW, Michael L, editors. Pharmacotherapy: A Pathophysiological Approach. 7 th ed. New Delhi: McGraw-Hill; 2008. p. 1-14.  Back to cited text no. 2
    




 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow